Tumor tissue sample
Item
tissue from an archived or fresh tumor sample
boolean
C0475358 (UMLS CUI [1])
Blood smear from peripheral blood Buffy Coat | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Item
a peripheral blood buffy coat sample is required for cll/sll.
boolean
C4296002 (UMLS CUI [1,1])
C2936475 (UMLS CUI [1,2])
C1302547 (UMLS CUI [2])
Mantle cell lymphoma | Lymphoma, Follicular | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Diffuse Large B-Cell Lymphoma
Item
patient has mantle cell lymphoma (mcl), follicular lymphoma (fl), or chronic lymphocytic leukemia (cll)/sll or diffuse large b cell lymphoma
boolean
C0334634 (UMLS CUI [1])
C0024301 (UMLS CUI [2])
C1302547 (UMLS CUI [3])
C0079744 (UMLS CUI [4])
Age
Item
patient > or = 18 years old
boolean
C0001779 (UMLS CUI [1])
ECOG performance status | Diffuse Large B-Cell Lymphoma
Item
eastern cooperative oncology group (ecog) performance status < or = 2. patients with dlbcl will have ecog < or = 1
boolean
C1520224 (UMLS CUI [1])
C0079744 (UMLS CUI [2])
White Blood Cell Count procedure | Hemoglobin measurement
Item
adequate white blood cells and hemoglobin
boolean
C0023508 (UMLS CUI [1])
C0518015 (UMLS CUI [2])
Renal function | Liver function
Item
good kidney and liver function
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
Glucose measurement, fasting
Item
fasting glucose < 160 mg/dl
boolean
C0202045 (UMLS CUI [1])
Cancer Other Absent
Item
no other malignancy
boolean
C1707251 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Contraceptive methods
Item
use of adequate birth control
boolean
C0700589 (UMLS CUI [1])
Cytotoxic Chemotherapy | Biological agents | Therapies, Investigational | Nitrosoureas | mitomycin
Item
treatment with cytotoxic chemotherapy, biologic agents, investigational therapies within 4 weeks, or nitrosoureas or mitomycin c within 6 weeks of study enrollment
boolean
C0677881 (UMLS CUI [1])
C0005515 (UMLS CUI [2])
C0949266 (UMLS CUI [3])
C0028210 (UMLS CUI [4])
C0002475 (UMLS CUI [5])
Small Molecule kinase inhibitor
Item
treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of the drug or its active metabolites (whichever is longer) of study enrollment
boolean
C1328819 (UMLS CUI [1,1])
C3537035 (UMLS CUI [1,2])
Phosphatidylinositide 3-Kinase Inhibitor | mTOR Inhibitor | AKT1 gene Inhibitor
Item
prior treatment with a pi3k, mtor, or akt inhibitor. prior treatment of mcl with temsirolimus is permitted in patients enrolled from countries where it is licensed for this indication.
boolean
C1519050 (UMLS CUI [1])
C2746052 (UMLS CUI [2])
C0812228 (UMLS CUI [3,1])
C1999216 (UMLS CUI [3,2])
Therapeutic radiology procedure
Item
radiation therapy within 2 weeks of enrollment
boolean
C1522449 (UMLS CUI [1])
Autologous hematopoietic stem cell transplant
Item
autologous stem cell transplantation within 16 weeks of enrollment
boolean
C2193200 (UMLS CUI [1])
Transplantation, Homologous
Item
prior allogeneic transplantation except for patients with r/r dlbcl who meet inclusion criteria
boolean
C0040739 (UMLS CUI [1])
Central Nervous System Involvement | Involvement Leptomeningeal
Item
central nervous system (cns) or leptomeningeal involvement. patients with dlbcl may have active cns or leptomeningeal involvement.
boolean
C4050309 (UMLS CUI [1])
C1314939 (UMLS CUI [2,1])
C0228126 (UMLS CUI [2,2])
Hepatitis B surface antigen positive | Serology positive Hepatitis C Antibodies
Item
positive hepatitis b surface antigen (hbsag) or hepatitis c antibody (anti-hcv) serology
boolean
C0149709 (UMLS CUI [1])
C0242089 (UMLS CUI [2,1])
C0166049 (UMLS CUI [2,2])
Primary central nervous system lymphoma
Item
primary cns lymphoma
boolean
C0280803 (UMLS CUI [1])
Mediastinal Large B-Cell Lymphoma
Item
primary mediastinal b-lymphoma
boolean
C1292754 (UMLS CUI [1])
Study Subject Participation Status | Considerations Incomplete
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])
C0518609 (UMLS CUI [2,1])
C0205257 (UMLS CUI [2,2])